Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × lortalamine × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Docetaxel 77 Radiotherapy 74 Prednisone 65 Leuprolide 51 Goserelin 49 Gemcitabine 48 Cisplatin 47 bicalutamide 46 enzalutamide 41 Androgen Antagonists 35 pembrolizumab 31 Abiraterone Acetate 30 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28 Mitomycin 28 Magnetic Resonance Spectroscopy 28 Carboplatin 27 Flutamide 25 Triptorelin Pamoate 23 Sunitinib 23 Nivolumab 23 Radiation 22 apalutamide 21 Doxorubicin 20 darolutamide 18 Gonadotropin-Releasing Hormone 17 cabozantinib 16 abiraterone 16 Specimen Handling 16 Paclitaxel 16 atezolizumab 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡